

Please amend claim 20, line 1 by deleting "claim 19" and inserting therefor --claim 24--.

REMARKS

Early reconsideration and allowance of the captioned application in view of the foregoing amendments and the remarks which follow are courteously requested. This amendment is accompanied by a petition extending the time for response to October 19, 1988.

The claims in the application are claims 1-21. Of these, claims 1, 16 and 19 have been cancelled and replaced respectively with claims 22-24. Accordingly the claims in the application are claims 2-15, 17-18 and 20-24.

Claims 1, 2, 5-11 and 16-21 have been rejected under 35 USC 112 on the allegation that the term "aryl" whether alone or as part of a substituent group is indefinite and otherwise not adequately supported by the enabling disclosure. While the applicants submit that the term "aryl" is sufficiently definite and supported by the disclosure so as to meet the requirements of 35 USC 112, nevertheless, to speed the prosecution of this case, the applicants have added new claims 22-24 to recite in place of the term "aryl" -phenyl optionally mono- or multiply-substituted by halogen, trifluoromethyl, lower-alkyl, lower-alkoxy, nitro or amino-. Support for this amendment may

be found throughout the specification as for example at page 2, lines 19-22.

Composition and method claims 16-21 have also been rejected under 35 USC 112 on the grounds of being indefinite on the allegation that the recitation in these claims of an effective amount of the compound of the invention does not recite the intended effect. In response to this ground of rejection, the applicants have, as suggested in the Office Action, added new claims 23 and 24 and amended claims 17-21 to recite -a calcium antagonistically effective amount-. Support for this amendment may be found throughout the specification as for example at page 4, lines 27-31 when read in conjunction with page 25, lines 1-12. The applicants thank the Examiner for this suggested amendment.

By the above amendments and argumentation, the applicants respectfully submit that both grounds of rejection under 35 USC 112, that is, the rejection of the term "aryl" as indefinite; and the rejection of composition and method claims for failing to recite what is the intended effect of the recited compounds, have been obviated. Accordingly, it is respectfully requested that this rejection be withdrawn.

Claims 3, 4 and 12-15 have been objected to as being dependent upon a rejected base claim. However, since by the above amendments and arguments, the base claims for these claims have been placed in allowable form, it is respectfully

submitted that claims 3, 4 and 12-15 are now also allowable. Therefore, it is respectfully requested that the objection to these claims be withdrawn.

Since all the claims are now in proper form, and patentably distinguished over the publications cited in the Information Disclosure Statements of August 16, 1988 and February 29, 1988, an early allowance of the application is courteously requested. Consideration of the publications cited in the August 16, 1988 Information Disclosure Statement is respectfully requested.

The Examiner is hereby authorized to call the undersigned attorney of record "collect" on any matter connected with this application. The telephone number is Area Code (201) 235-5171. In the absence of the undersigned attorney of record, the call will be accepted by another attorney empowered in this application.

Respectfully submitted,

Matthew Boxer
Attorney for Applicant(s)

Matthew Boxer
(Reg. No. 28495)
340 Kingsland Street
Nutley, New Jersey 07110

MB/ada
4495P